The 2018 accelerated approval of Vitrakvi was converted to full approval based on results from three trials in adult and pediatric patients.

The company expects early cohort data this year from the trial assessing the calpain-2-targeted antisense oligonucleotide therapy.

ACMG, NSGC, and others in the genetics community are monitoring whether the widely used online clinical genetics database ...

With an arsenal of antibody assets based on IgE, IgA, and IgG, the newly combined company has opportunities across cancer indications.